netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Research to Prevent Blindness Grantee Dr. Gregg Semenza Wins Nobel Prize in Medicine

NEW YORK, NY, October 10, 2019—Research to Prevent Blindness (RPB) is pleased to announce that RPB Stein Innovation Awardee Gregg Semenza, MD, PhD, at Johns Hopkins University School of Medicine, has been named a winner of the 2019 Nobel Prize in Medicine. Dr. Semenza and two co-recipients—William G. Kaelin, Jr. of the Dana-Farber Cancer Institute and Sir Peter J. Ratcliffe of Oxford University—were selected as Nobel Laureates for “seminal discoveries… [revealing] the mechanism for one of life’s most essential adaptive processes,” namely, “how oxygen levels affect cellular metabolism and physiological function,” according to The Nobel Assembly at Karolinska Institutet. The work creates the potential for the development of new treatments for a host of diseases, including cancer, coronary artery disease, anemia, stroke and blinding eye diseases.

Nobel Laureate Dr. Gregg Semenza (right) and a colleague work in his lab at Johns Hopkins University School of Medicine. 

The work of all three Laureates builds upon each other to show that oxygen sensing is a vital function across many cell types. Specifically, Dr. Semenza discovered a protein complex that binds to a DNA segment in an oxygen-dependent manner, which he named hypoxia-inducible factor (HIF). When oxygen sensing in cells fails or is interrupted because HIF cannot properly bind to DNA, it can lead to disease in many different areas of the body, depending on which cells are affected.

Dr. Semenza, who is the C. Michael Armstrong Professor of Pediatrics, Medicine, Oncology, Radiation Oncology, Biological Chemistry, and Genetic Medicine, is using his RPB grant to apply and extend the knowledge gained during his Nobel Prize-winning work to eye diseases that are characterized by extraneous blood vessel growth, or angiogenesis.

“We and others have shown the critical role of HIF in stimulating angiogenesis in the eye. With support from RPB, we are now developing HIF inhibitors as a potential therapy for ocular disorders that are associated with neovascularization, such as wet age-related macular degeneration and diabetic retinopathy,” said Dr. Semenza.

“We are so proud of Dr. Semenza’s incredible research accomplishments and are thrilled that with an RPB grant, he is focusing his Nobel-caliber knowledge and skills on the development of treatments for blinding eye diseases,” said RPB President Brian Hofland, PhD.

Dr. Semenza will receive his Nobel Prize in December 2019 at a ceremony in Sweden. His RPB Stein Innovation Award is active through the end of 2020.

To learn more about Dr. Semenza’s Nobel Prize in Medicine, visit https://www.nobelprize.org/prizes/medicine/
To learn more about his ongoing research, visit  https://www.hopkinsmedicine.org/research/labs/gregg-semenza-lab.

About Research to Prevent Blindness

Research to Prevent Blindness (RPB) is the leading nonprofit organization supporting eye research directed at the prevention, treatment or eradication of all diseases that damage and destroy sight. As part of this purview, RPB also supports efforts to grow and sustain a robust and diverse vision research community. Since it was founded in 1960 by Dr. Jules Stein, RPB has awarded more than $368 million in research grants to the most talented vision scientists at the nation’s leading medical schools. As a result, RPB has been associated with nearly every major breakthrough in the understanding and treatment of vision loss in the past 50+ years. Learn more at www.rpbusa.org.

Related News: Diabetic Retinopathy, Feature Story, For the Media, Macular Degeneration, Top Story

RPB logo

RPB and Partners Award $1.2 Million In Grants for Novel AMD Research

Four new grantees received the Catalyst Awards for Innovative Research Approaches for AMD.

Read More

 
CDA 30th Anniversary book

The Career Development Award Turns 30: Celebrating a Generation of Support for Early-Career Scientists

CDA founded 30 years ago as one of the few private sources of funding aimed specifically at early-career vision researchers.

Read More

 
Retinal image of person with Alzheimer's disease

Could An Eye Exam Reveal Alzheimer’s Disease?

Study from RPB-supported researchers at Duke University suggests loss of blood vessels in retina reflect changes in brain health.

Read More

 
Gregory Schwartz in the lab

New Findings on Blood Vessel Regulation

A study from an RPB-supported researcher at Northwestern University School of Medicine could speed up the diagnosis of retinal diseases.

Read More

 
NEI Audacious Goals image and text

RPB-SUPPORTED RESEARCHERS INTEGRAL TO NEI’S AUDACIOUS GOALS INITIATIVE

Vision scientists who have received RPB funding will help lead all five research teams, which will seek to accelerate development of regenerative treatments for blindness.

Read More

 
2018 class of EVS

EMERGING VISION SCIENTISTS EDUCATE, THANK CONGRESS FOR RESEARCH APPROPRIATIONS

(NAEVR) held its Fourth Annual Emerging Vision Scientists (EVS) Day on Capitol Hill and twenty early-stage investigators participated.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.